Prognostic Markers for a Better Follow-up in Head and Neck Cancer.
Karolinska Institutet
20 participants
Feb 12, 2014
OBSERVATIONAL
Conditions
Summary
To identify tumor specific DNA mutations and aberrations and to follow these in blood over time to predict treatment response/survival and secondly to correlate presence of these markers in blood to pathological parameters (LVI, Pn, WPOI and margins), radiological findings and to tumor stage.
Eligibility
Inclusion Criteria3
- Patient diagnosed with head and neck cancer
- Treatment includes surgery
- Consent to participate
Exclusion Criteria4
- No consent
- Age below 18 years
- No surgery
- No tumor material to sample
Interventions
A piece from tumor and a blood sample will be collected during surgery. DNA will be extracted and presence of tumor specific mutations/aberrations will be analysed with a DNA exome seq panel. Presence of identified markers will be followed in blood samples with the same panel and these blood samples will be collected in routine follow-up during the first two years. Presence of markers over time in blood will be correlated to outcomes 1-5.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06094985